Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Cerebrospinal Fluid | 3 | 2019 | 234 | 1.41 | Why? |
| HIV Infections | 14 | 2019 | 11620 | 1.01 | Why? |
| Neopterin | 3 | 2019 | 69 | 1.00 | Why? |
| Rifampin | 3 | 2019 | 276 | 0.83 | Why? |
| Arylamine N-Acetyltransferase | 1 | 2019 | 15 | 0.80 | Why? |
| HIV Integrase Inhibitors | 2 | 2018 | 173 | 0.79 | Why? |
| Isoniazid | 2 | 2019 | 105 | 0.78 | Why? |
| Tinea | 1 | 2019 | 22 | 0.76 | Why? |
| Multidrug Resistance-Associated Proteins | 1 | 2018 | 29 | 0.74 | Why? |
| Immune Reconstitution Inflammatory Syndrome | 1 | 2019 | 66 | 0.73 | Why? |
| AIDS Dementia Complex | 1 | 2018 | 48 | 0.68 | Why? |
| AIDS-Related Opportunistic Infections | 2 | 2018 | 260 | 0.68 | Why? |
| Valproic Acid | 1 | 2018 | 114 | 0.67 | Why? |
| Central Nervous System Infections | 1 | 2019 | 158 | 0.66 | Why? |
| Meningitis, Bacterial | 1 | 2018 | 111 | 0.66 | Why? |
| Neurocognitive Disorders | 1 | 2018 | 99 | 0.64 | Why? |
| HIV Seropositivity | 1 | 2019 | 320 | 0.63 | Why? |
| Ceftriaxone | 1 | 2018 | 365 | 0.62 | Why? |
| Lymphoproliferative Disorders | 1 | 2017 | 110 | 0.59 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 275 | 0.57 | Why? |
| Anti-HIV Agents | 5 | 2019 | 2209 | 0.52 | Why? |
| Anti-Retroviral Agents | 2 | 2019 | 1099 | 0.51 | Why? |
| Neoplasm Proteins | 1 | 2018 | 501 | 0.49 | Why? |
| Anticonvulsants | 1 | 2018 | 634 | 0.48 | Why? |
| Viral Load | 7 | 2021 | 15850 | 0.47 | Why? |
| Central Nervous System | 1 | 2018 | 701 | 0.47 | Why? |
| Bacteria | 2 | 2020 | 1897 | 0.46 | Why? |
| HIV-1 | 5 | 2019 | 3365 | 0.46 | Why? |
| Polymorphism, Single Nucleotide | 4 | 2019 | 3607 | 0.44 | Why? |
| Cerebrovascular Disorders | 1 | 2019 | 1040 | 0.42 | Why? |
| Viremia | 1 | 2017 | 1020 | 0.39 | Why? |
| Bacterial Infections | 1 | 2020 | 2229 | 0.32 | Why? |
| Atazanavir Sulfate | 2 | 2018 | 213 | 0.30 | Why? |
| Tuberculosis | 2 | 2019 | 2895 | 0.30 | Why? |
| HIV Protease Inhibitors | 2 | 2018 | 434 | 0.27 | Why? |
| Antiretroviral Therapy, Highly Active | 3 | 2017 | 952 | 0.25 | Why? |
| Antitubercular Agents | 2 | 2019 | 775 | 0.23 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.22 | Why? |
| Aging | 1 | 2017 | 3581 | 0.22 | Why? |
| Heparin, Low-Molecular-Weight | 2 | 2020 | 1731 | 0.21 | Why? |
| Antineoplastic Agents | 1 | 2017 | 3550 | 0.21 | Why? |
| Tenofovir | 3 | 2018 | 449 | 0.21 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.20 | Why? |
| Factor Xa | 1 | 2020 | 113 | 0.20 | Why? |
| Pharmacogenetics | 2 | 2017 | 222 | 0.19 | Why? |
| S100 Calcium Binding Protein beta Subunit | 1 | 2019 | 63 | 0.19 | Why? |
| 14-3-3 Proteins | 1 | 2019 | 55 | 0.19 | Why? |
| Pharmacogenomic Variants | 1 | 2019 | 112 | 0.19 | Why? |
| tau Proteins | 1 | 2019 | 162 | 0.18 | Why? |
| Alkynes | 1 | 2018 | 98 | 0.18 | Why? |
| CCR5 Receptor Antagonists | 1 | 2018 | 66 | 0.18 | Why? |
| Leukoencephalopathy, Progressive Multifocal | 1 | 2018 | 55 | 0.17 | Why? |
| Benzoxazines | 1 | 2018 | 103 | 0.17 | Why? |
| CD4 Lymphocyte Count | 3 | 2018 | 1517 | 0.17 | Why? |
| Amyloid beta-Peptides | 1 | 2019 | 185 | 0.17 | Why? |
| Parasites | 1 | 2017 | 39 | 0.17 | Why? |
| Membrane Transport Proteins | 1 | 2018 | 152 | 0.16 | Why? |
| CD4-CD8 Ratio | 1 | 2017 | 235 | 0.16 | Why? |
| Oxazines | 1 | 2018 | 279 | 0.16 | Why? |
| Survival Analysis | 3 | 2019 | 7592 | 0.15 | Why? |
| Adenine | 1 | 2018 | 463 | 0.15 | Why? |
| Cyclopropanes | 1 | 2018 | 332 | 0.15 | Why? |
| Uganda | 1 | 2019 | 1057 | 0.14 | Why? |
| Drug Monitoring | 2 | 2020 | 1408 | 0.14 | Why? |
| Piperazines | 1 | 2018 | 445 | 0.14 | Why? |
| Middle Aged | 17 | 2022 | 270681 | 0.13 | Why? |
| Female | 20 | 2021 | 380317 | 0.13 | Why? |
| Male | 18 | 2022 | 367725 | 0.13 | Why? |
| Enoxaparin | 1 | 2020 | 1064 | 0.13 | Why? |
| Fungi | 1 | 2017 | 471 | 0.13 | Why? |
| Italy | 4 | 2021 | 38444 | 0.12 | Why? |
| Cytomegalovirus | 1 | 2018 | 600 | 0.12 | Why? |
| Adult | 12 | 2021 | 244371 | 0.12 | Why? |
| Pyridones | 1 | 2018 | 738 | 0.12 | Why? |
| Nasal Mucosa | 1 | 2020 | 1218 | 0.12 | Why? |
| Biomarkers | 4 | 2020 | 23361 | 0.11 | Why? |
| Stents | 1 | 2019 | 916 | 0.11 | Why? |
| Plasma | 2 | 2019 | 1809 | 0.11 | Why? |
| Cytomegalovirus Infections | 1 | 2018 | 667 | 0.11 | Why? |
| Health Personnel | 2 | 2022 | 29646 | 0.11 | Why? |
| Humans | 28 | 2022 | 930598 | 0.11 | Why? |
| Retrospective Studies | 8 | 2021 | 105322 | 0.11 | Why? |
| Drug Interactions | 1 | 2018 | 1653 | 0.10 | Why? |
| T-Lymphocyte Subsets | 1 | 2017 | 1387 | 0.10 | Why? |
| Multivariate Analysis | 2 | 2018 | 5440 | 0.10 | Why? |
| RNA, Viral | 6 | 2021 | 32276 | 0.10 | Why? |
| Drug Combinations | 1 | 2019 | 3852 | 0.09 | Why? |
| Precision Medicine | 1 | 2017 | 1477 | 0.08 | Why? |
| Blood Coagulation | 1 | 2020 | 2768 | 0.08 | Why? |
| DNA, Viral | 1 | 2018 | 2521 | 0.08 | Why? |
| Cross-Sectional Studies | 5 | 2022 | 53120 | 0.08 | Why? |
| Ritonavir | 2 | 2018 | 4212 | 0.08 | Why? |
| Predictive Value of Tests | 2 | 2020 | 9537 | 0.08 | Why? |
| CD4-Positive T-Lymphocytes | 2 | 2018 | 4545 | 0.07 | Why? |
| Aged | 8 | 2021 | 215776 | 0.07 | Why? |
| Acute Coronary Syndrome | 1 | 2019 | 2107 | 0.07 | Why? |
| Drug Therapy, Combination | 4 | 2018 | 7268 | 0.07 | Why? |
| Coronary Artery Disease | 1 | 2019 | 2570 | 0.07 | Why? |
| Comorbidity | 2 | 2019 | 34796 | 0.06 | Why? |
| Aged, 80 and over | 5 | 2020 | 88759 | 0.06 | Why? |
| Viruses | 1 | 2017 | 2238 | 0.06 | Why? |
| Occupational Exposure | 1 | 2022 | 4742 | 0.06 | Why? |
| Percutaneous Coronary Intervention | 1 | 2019 | 3646 | 0.06 | Why? |
| Disease Progression | 1 | 2021 | 13580 | 0.06 | Why? |
| Vitamin D | 1 | 2017 | 2904 | 0.06 | Why? |
| Brain | 1 | 2018 | 5133 | 0.05 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2017 | 5837 | 0.05 | Why? |
| Respiratory Tract Infections | 1 | 2020 | 6817 | 0.05 | Why? |
| Anticoagulants | 1 | 2020 | 9563 | 0.05 | Why? |
| HIV Seronegativity | 1 | 2018 | 112 | 0.04 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.04 | Why? |
| Thrombosis | 1 | 2020 | 7504 | 0.04 | Why? |
| Economics, Pharmaceutical | 1 | 2017 | 61 | 0.04 | Why? |
| Registries | 1 | 2018 | 12327 | 0.04 | Why? |
| Pregnancy Trimesters | 1 | 2017 | 90 | 0.04 | Why? |
| Virus Replication | 1 | 2018 | 14331 | 0.04 | Why? |
| Antiviral Agents | 3 | 2020 | 41703 | 0.04 | Why? |
| Metals | 1 | 2019 | 182 | 0.04 | Why? |
| Multiple Chronic Conditions | 1 | 2017 | 115 | 0.04 | Why? |
| Emtricitabine | 1 | 2017 | 202 | 0.04 | Why? |
| Prevalence | 1 | 2019 | 25773 | 0.04 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2018 | 309 | 0.04 | Why? |
| Pregnancy Trimester, Third | 1 | 2018 | 445 | 0.04 | Why? |
| Prosthesis Design | 1 | 2019 | 594 | 0.04 | Why? |
| Madin Darby Canine Kidney Cells | 1 | 2018 | 640 | 0.04 | Why? |
| Anti-Bacterial Agents | 1 | 2018 | 10083 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.04 | Why? |
| Animals | 4 | 2018 | 78931 | 0.04 | Why? |
| Off-Label Use | 1 | 2020 | 553 | 0.04 | Why? |
| Pregnancy Complications, Infectious | 2 | 2018 | 11559 | 0.04 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.03 | Why? |
| Polypharmacy | 1 | 2017 | 347 | 0.03 | Why? |
| Chromatography, High Pressure Liquid | 1 | 2017 | 669 | 0.03 | Why? |
| Life Expectancy | 1 | 2018 | 474 | 0.03 | Why? |
| Prospective Studies | 4 | 2020 | 43301 | 0.03 | Why? |
| Virus Activation | 1 | 2018 | 480 | 0.03 | Why? |
| Drug-Eluting Stents | 1 | 2019 | 562 | 0.03 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.03 | Why? |
| Risk Factors | 2 | 2019 | 71621 | 0.03 | Why? |
| Observational Studies as Topic | 1 | 2019 | 1887 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Alleles | 1 | 2017 | 1557 | 0.03 | Why? |
| Child | 1 | 2020 | 70012 | 0.03 | Why? |
| Dogs | 1 | 2018 | 2529 | 0.03 | Why? |
| Immunomodulation | 1 | 2020 | 1472 | 0.03 | Why? |
| Health Services for the Aged | 1 | 2017 | 602 | 0.03 | Why? |
| Adolescent | 1 | 2020 | 86841 | 0.02 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.02 | Why? |
| Young Adult | 1 | 2020 | 93724 | 0.02 | Why? |
| Treatment Outcome | 3 | 2020 | 51732 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.02 | Why? |
| Pilot Projects | 1 | 2020 | 5182 | 0.02 | Why? |
| Drug Resistance, Bacterial | 1 | 2017 | 1414 | 0.02 | Why? |
| Leukocytes, Mononuclear | 1 | 2017 | 2115 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2022 | 10017 | 0.02 | Why? |
| Pregnancy | 2 | 2018 | 23879 | 0.02 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.02 | Why? |
| Time Factors | 2 | 2019 | 31397 | 0.02 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.01 | Why? |
| Alanine | 1 | 2018 | 5687 | 0.01 | Why? |
| Models, Biological | 1 | 2017 | 4907 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.01 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.01 | Why? |
| Infant, Newborn | 1 | 2017 | 23105 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
| Hospital Mortality | 1 | 2019 | 22087 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.01 | Why? |
| Cohort Studies | 1 | 2017 | 36005 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2022 | 29620 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.01 | Why? |
| Antibodies, Viral | 1 | 2022 | 51949 | 0.01 | Why? |
| Pandemics | 1 | 2020 | 389249 | 0.00 | Why? |
Calcagno's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(173)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(102)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_